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Summary We have examined the biological properties of CEA6, a human carcinoembryonic antigen (CEA)-specific single-chain Fv (scFv)
isolated by phage display, and five related clones derived by affinity maturation and selected for improved off-rate (Kff). All clones bind
strongly and specifically to CEA-positive human tumours by immunocytochemistry and show negligible cross-reactivity with normal colon.
Flow cytometry of scFv on human liver cells indicates a shift in fine epitope specificity resulting from mutagenesis. All monomeric scFv have
been radioiodinated, retaining effectively full binding activity. A single intravenous injection into nude mice bearing human colon tumour
xenografts confirms tumour targeting in all cases. As reported in other studies, the kidney is the main route of elimination of scFv at early time
points. Tumour binding of the parental antibody CEA6 consistently gives the highest tumour-blood ratios at 24 h (mean 16:1). Clone T06D11,
which has a sevenfold reduced K0ff relative to CEA6, showed no difference in tumour uptake at 24 h but persisted at the tumour site for longer
than CEA6. This study demonstrates a possible correlation between binding affinity and tumour residence time when examined in this model.
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Advances in recombinant antibody technology have allowed many
ofthe problems encountered in antibody targeting oftumours to be
overcome (Huston et al, 1993). Poor tumour penetrance of whole
immunoglobulin has been addressed through the use of smaller
fragments derived both enzymatically and by recombinant
methods (Yokota et al, 1992; Hu et al, 1996; Rowlinson-Busza et
al, 1996). Further advantages of fragments are their rapid extra-
vasation and pharmacokinetic clearance, which are clearly
contributing factors in their improved performance as imaging
agents (Colcher et al, 1990; Milenic et al, 1991; Verhaar et al,
1995). Moreover, the immunogenicity of rodent monoclonal anti-
bodies (mAbs) has been reduced either by humanization strategies
or by de novo isolation of antibody fragments from combinatorial
libraries of human V genes (reviewed by Johnson and Chiswell,
1993). Rapid expression in bacteria has greatly assisted the study
ofimproved engineered antibody fragments and has avoided time-
consuming and expensive mammalian cell expression systems.
The isolation and characterization of scFv from large phage
display libraries has demonstrated several instances where the disso-
ciation constant of the molecule, and more specifically the off-rate
(Kodf), is the main predictive factor in performance in in vitro bioas-
says (Thompson et al, 1996; Schier et al, 1996; Roberts et al, in
preparation). The relationship between binding kinetics and tumour
targeting efficiency is rather more complicated, mainly because so
many additional factors (tumour size, antigen density and rate of
turnover, epitope, size and charge of antibody, dose, isotope and
labelling chemistry used, presence ofcirculating antigen) are known
to influence the uptake of radiolabelled antibody into tumours
(reviewed by Goldenberg et al, 1990). Although it is generally
thought that the best cancer therapeutic would have ahigh affinity for
Received 12 September 1997
Revised22 December 1997
Accepted 20 January 1998
Correspondence to: D Allen
antigen and a slow rate of dissociation from the tumour cell surface,
this conclusion has been drawn from studies of rodent-derived anti-
bodies. Whether the same will be true of completely human anti-
bodies awaits the outcome ofmore extensive in vivo studies.
The best means of exploring the role of affinity for antigen in
tumour targeting is a parallel comparison of several structurally
related targeting molecules, differing from one another only in their
affinity (Langmuir et al, 1992; Schlom et al, 1992). We have devel-
oped such a panel ofmolecules through the structural diversification
of scFv CEA6 (Vaughan et al, 1996), by CDR3 mutagenesis and
chain shuffling (Osbourn et al, 1996). We have used radioiodinated
scFv of five mutants and the CEA6 parent in nude mice bearing
human colon tumour xenografts, to measure the biodistribution at
various times after intravenous administration. We have found that,
for scFv antibodies whose pharmacokinetic clearance is relatively
rapid, a reduction in K, to within an order of magnitude has a rela-
tively modest effect on the association ofantibody with tumour.
In the investigation by flow cytometry ofCEA specificity ofCEA6
and all five affinity-matured scFv, an immortalized human liver cell
line was used as a negative control forCEA expression. We made the
unexpected observation that, although none of the affinity-matured
clones bound to this cell line, a subpopulation ofcells was recognized
by CEA6. This difference in fine antigenic specificity was not seen
when the scFv were used for immunocytochemical staining of
sections of normal human liver. However, the result demonstrates
how the structural diversification of antibodies during affinity matu-
ration may have unforeseen effects on fine antigenic specificity.
MATERIALS AND METHODS
Affinity matured CEA-specific scFv
The antibodies which are the subject of this study have been
described in detail in Osbourn et al (1996). Briefly, the parental
clone, CEA6, and all five mutants derived from it (HBB11,
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T06D10, T06D4, TO6D12 and TO6D11) have a range ofdissoci-
ation constants (Kd) for CEA when measured by surface plasmon
resonance, mainly through differences in Koff, with TO6D 1I
having the slowest off-rate relative to CEA6 (Table 1). All six
scFv, as well as the positive control MFE23 and negative controls
FITC-E2 and Hb-1 (all described further below), had been
subcloned for expression from the gene III-containing phagemid
vector pCANTAB6 into a pUC 19-derived plasmid.
Growth, expression and purification of scFv
Colonies were inoculated into 50 ml of 2TY broth containing 2%
(w/v) glucose and 100 .tg ml-' ampicillin (2YTGA) and incubated
overnight at 30°C. The overnight culture was added to 500 ml of
2TYA containing 0.1% (w/v) glucose and grown at 30°C in an
orbital shaker to an OD600 of 1.0. IPTG was added to 1 mm final
concentration and the cultures induced for 3 h at 30°C. Cells were
pelleted at 5000 r.p.m. for 10min in a precooled rotor (4°C;
Sorvall GSA) and periplasmic preparations of scFv were made by
resuspending the pellets in 25 ml ice-cold 50 mM Tris-HCl pH 8.0,
20% sucrose, 1 mM EDTA and incubating on ice for 15 min.
Insoluble material was removed by centrifugation and magnesium
chloride was added to 1 mm final concentration. The scFv super-
natant was added to prewashed NTA-agarose (Qiagen) and incu-
bated at 4°C overnight for purification by immobilized metal
affinity chromatography (IMAC) via the carboxy-terminal hexa-
histidine tail. Material bound to NTA-agarose was eluted in
phosphate buffer containing 250 mm imidazole. Monomeric scFv
was fractionated from the eluate by fast protein-liquid
chromatography (FPLC) on a Superdex 75 HRI 0/30 column
(Pharmacia) and detected on-line by UV absorbance at 280 nm.
SDS polyacrylamide gel electrophoresis (SDS-PAGE)
Samples of FPLC-purified scFv were analysed on 10-15%
gradient gels using the Phast electrophoresis system (Pharmacia).
For analysis ofthe proportion ofdimeric scFv, gels were run under
non-reducing conditions. After electrophoresis the gels were silver
stained according to Pharmacia methods.
Enzyme-linked immunosorbent assay (ELISA)
Flexible 96-well microtitre plates (Falcon) which had been coated
overnight at 37°C with 50 ng per well CEA (Genzyme) in distilled
waterwere washedthree times in phosphate-buffered saline (PBS) and
blocked for 2 h at room temperature (RT) in PBS containing 3% (w/v)
skimmed milkpowder (3MPBS). Plates were washed three times with
PBS, then 50 tl per well purified scFv (preblocked with MPBS) was
added for 1 h at RT. Plates were washed three times in PBS containing
0.1% (v/v) Tween 20 (Sigma) (PBST) and three times with PBS.
Detection ofbound scFv was with 1:200diluted anti-myctag antibody,
9E10 (Munro and Pelham, 1986), for 1 h at RT. After washing,
the assay was developed with 1:5000 diluted alkaline phosphatase
conjugated goat anti-mouse IgG (Pierce) at RT for I h. Plates were
washed, rinsed in0.9% sodiumchloride andthechromagenic substrate
pNPP (Sigma) was added. Absorbance was measured at 405 nm.
Dissociation constant measurement
Surface plasmon resonance (SPR) for measuring the kinetics of scFv
binding to CEA immobilized on aBlAcore sensorchip wascarriedout
for all samples used for in vitro and in vivo binding experiments: the
methods used have been described previously (Osbourn et al, 1996).
Immunocytochemistry
IMAC-purified scFv were used to detect CEA expressed in
paraffin-embedded formalin-fixed sections from different tissue
sources (BioMedix). Sections were de-waxed in Histoclear then
washed twice with 100% ethanol, once with 70% ethanol, rehy-
drated in distilled water (all 5 min each) and rinsed in PBST.
Endogenous alkaline phosphatase activity was then blocked with
20% acetic acid for 15 min, rinsed with PBST, then blocked for
1 h in 1% bovine serum albumin (BSA) in PBS (PBSB). After
rinsing, monomeric scFv diluted to 10,g ml-' in PBSB were
applied and incubated in a humidified atmosphere overnight at
4°C. Slides were rinsed three times with PBST (2 min each), then
incubated with 1:100 diluted 9E10 in PBSB for 1 h at RT. After
rinsing as before, alkaline phosphatase conjugated goat anti-
mouse IgG (Jackson Laboratories; 1:100 diluted in PBS/10% fetal
calf serum) was added and the incubation continued for 1 h.
Bound antibody was detected with Fast Red substrate, then the
section was counterstained with haematoxylin and mounted.
Flow cytometry
HeLa cells (1.0 x 101 cells) which had been stably transfected with
human CEA, or Chang human liver cells, were incubated with
5 ,ug purified scFv in 100 gl PBS/0.5% BSA for 1 h at RT. Cells
were washed once with 10 ml PBS/0.5% BSA, incubated with
9E10 at 25 gg ml-' in 100 .tl PBS/0.5% BSA for I h, then washed
and incubated with a 1:200 dilution ofFITC-conjugated anti-mouse
IgG (Sigma) in 100 gl PBS/0.5% BSA for 1 h. After the final
washing step, cell fluorescence was measured using a Coulter-
EPISXL-MCL flow cytometer. Fluorescence was measured using
the FLI channel (emission below 550 nm) and plotted on a loga-
rithmic scale against the number ofcells.
Radioiodination
Eight FPLC-purified, monomeric scFv were labelled with iodine-
125 (1251) for biodistribution studies in tumour-bearing mice (see
below). Six CEA-specific scFv (CEA6, HBB11, T06D10, T06D4,
T06D12 and TO6D11) were selected to span a range of Koff
measurements for CEA, as measured by SPR (Table 1; Osbourn et
al, 1996). Control scFv were as follows: a human scFv FITC-E2,
specific for the hapten fluorescein (Vaughan et al, 1996) was
Table 1 Affinity-matured scFv derivatives of CEA6
scFv Origin Kd (M) Kon(M-'s-' K0ff(s-1) Relative
reduction in Kff,
CEA6 Parent 7.7 x 10-9 8.0 x 105 6.2 x 10-3
HBB11 VH CDR3 mutagenesis 2.0 x 10-9 1.0 x 106 2.0 x 10-3 3.1-fold
TO6D10 VH CDR3 mutagenesis 1.4 x 10-9 1.0 x 106 1.4 x 10-3 4.3-fold
T06D4 Light chain shuffle 8.0 x 10-9 5.0 x 105 4.0 x 10-3 1.6-fold
T06D12 Light chain shuffle 3.6 x 10-9 9.0 x 105 3.2 x 10-3 1.9-fold
TO6D11 TO6D10 VH, TO6D12 VL 6.0 x 10-10 1.5 x 106 9.0 x 104 6.9-fold
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A
Figure 1 Immunocytochemical staining with (A and B) CEA6, (C and D) TO6D11 and (E and F) Hb-1 scFv at 10 'g ml-1 on sections of human colon
adenocarcinoma (A, C and E) and normal human colon tissue (B, D and F). Magnification x 20
included as a negative control, while a murine CEA-specific scFv,
MFE23, kindly provided by Dr K Chester, Royal Free Hospital,
London, UK, was used as a positive control. MFE23 has previously
been shown to localize to CEA-expressing tumours in mice and to
metastatic liver deposits of colorectal tumours in humans (Chester
et al, 1994; Verhaar et al, 1995; Begent et al, 1996).
lodination was carried out using a modification of the lodoGen
method (Pimm and Gribben, 1993). Monomeric scFv were exposed
to Na'251 (ICN) in 1.5 ml microfuge tubes that were precoated with
the oxidizing agent lodo-Gen (Pierce) under nitrogen gas, according
to the manufacturer's instructions. The ratioof 1251 to monomeric scFv
was 500 ,Ci:100 ,tg in the presence of 100 ,tg oflodoGen. The iodi-
nation reaction was allowed to proceed for 10 min on ice in a total
volume of not more than 500,l of borate buffer pH 8.6 [one part
0.1 M borate to one part 0.9% (v/v) sodium chloride]. lodinated scFv
was separated from '251+ by gel filtration on a Sephadex G25 column
(PD10, Pharmacia). The column was pre-blocked with 5% BSA in
PBS followed by six void-volume washes in PBS prior to loading of
the iodination reaction mixture. lodinated scFv were eluted in PBS
and stored at 4°C for not more than 5 days prior to administration to
mice. Samples of radiolabelled scFv were checked prior to in vivo
administration to ensure against dimerized ordegraded material.
Specific activity of 1251-labelled scFv
The specific activity of the protein was estimated by counting seri-
ally diluted aliquots of the peak fraction (in PBS/1% BSA) in a
gamma-counter (Cobra II, Canberra Packard). The calculated
specific activity of the labelled scFv was between 0.5-2 pCi ,tg-'.
Stability ofthe labelled conjugate was measured by thin layer chro-
matography on silica gel using 10% trichloracetic acid (TCA) as the
mobile phase: this confirmed that for all ['251]scFv, 95-97% of the
counts were TCA precipitable. CEA reactivity of the labelled scFv
was confirmed by measuring binding to a 0.5-ml CEA-Sepharose
column, provided by the Department of Clinical Oncology, Royal
Free Hospital. A 50pi aliquot of ['251]scFv, diluted to give approxi-
mately 50 000 c.p.m. was loaded onto the column and three void-
volume washes with PBS removed CEA non-reactive material,
which was retained for gamma counting. The percentage of bound
(CEA reactive) ['251]scFv was measured from material eluted with
3 M ammonium thiocyanate and gamma counting as above. The
percentage CEA binding of labelled CEA-specific human scFv was
compared with that of a human scFv specific for fluorescein (FITC-
E2): this scFv exhibited no cross-reactivity to CEA by ELISA.
LS174T xenografts
LS174T is a human colon adenocarcinoma cell line maintained by
serial passage in outbred MF1 athymic nude (niulnu) mice. In nude
mice itproduces moderately differentiatedCEA-producing adenocar-
cinomas that secrete no measurable CEA into the circulation (Pedley
et al, 1993). Tumour localization ofboth murine and chimaeric CEA-
specific antibodies, antibody fragments and scFv has been demon-
stratedusing this tumourxenograft model (Harwoodetal, 1985; King
et al, 1994; Verhaar et al, 1995; Hu et al, 1996). The biodistribution
and tumour localization of ['251]scFv were examined in female MFI
nulnu mice (weighing 20-25 g) bearing heterotransplanted LS174T
tumours (at a mean size of650 mg; range 500-800 mg).
Biodistribution studies
All [1251]scFv (0.1 mg ml-') were diluted in PBS and/or unlabelled
scFv to achieve a radioactive concentration of between 50-
100 pCi ml-' for injection. Groups of mice each received a single
0.1 ml (10 ,ug; 5-10 tCi) bolus dose ofone ofthe eight antibodies,
in the lateral tail vein. A 10 ,l aliquot was retained and the c.p.m.
measured to confirm the mean injected dose. Groups of four mice
were necropsied at various times from 3 h to 48 h following injec-
tion. Samples of blood, liver, kidney, lung, spleen, colon, skeletal
muscle, femur and tumour were removed, weighed and suspended
through an equivalent volume of 7 M potassium hydroxide prior to
gamma counting. Incorporated radioactive counts were expressed
per g oftissue as a percentage of the measured injected dose.
RESULTS
Purification of monomeric scFv for in vitro and in vivo
experiments
In order to maximize the consistency of the experimental results, all
scFv listed in Table 1 were purified by IMAC and FPLC then
quantitated spectrophotometrically and analysed by non-reducing
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SDS-PAGE. Gel analysis was carried out because all scFv had been
cloned into a pUC-based vector (for soluble expression in the absence
of gene III) with a free cysteine residue at the carboxy terminus. This
allowed site-specific modification of the scFv for studies reported
elsewhere; however, it also had the effect of leading to dimer forma-
tion during scFv extraction. As this study aimed to correlate the
biological properties of scFv with the off-rate component of affinity,
all clones were purified as monomers to eliminate effects ofbivalency.
Immunocytochemistry on fixed tissue sections
Clones CEA6, HBB 1, T06D10, T06D4, T06D12 and TO6D1,
as well as MFE23 and a negative control scFv Hb-1 (Parsons et al,
1996), were examined for staining of ten samples each of normal
human colon, colonic polyps/adenomas and colonic adenocarci-
nomas. No scFv showed completely uniform staining of every
sample in a panel of ten, although a clear consensus could be
reached: all CEA-specific clones stained moderately differentiated
to well-differentiated colonic adenocarcinomas the most intensely,
with less intense staining of colonic polyps and adenomas and
weak to moderate staining of normal colon tissues. Staining of
moderately differentiated tumours was localized to the basal
surfaces of glands and within the lumen. Staining of well-differen-
tiated tumours was confined to the mucin-producing goblet cells.
Where staining of normal colon was seen, it was mainly located on
normal surface epithelium, goblet cells and crypt epithelium.
Figure I shows the staining ofnormal vs malignant colon tissue for
CEA6, TO6DI I (the clone with the greatest difference in Kd from
CEA6) and the negative control Hb-1. Neither TO6D 11 nor any of
the other affinity-matured clones (not shown) showed any broad
shift in specificity relative to CEA6 when analysed on these tissues.
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Altered fine specificity for a human liver cell line
In parallel with analysis ofCEA specificity ofall clones by ELISA
and immunocytochemistry, we also examined their binding to
CEA-expressing transfected HeLa cells by flow cytometry, where
CEA is expressed at lower levels than on tumours (- 10 000 copies
percell). As observed previously, CEA6 showed an approximately
tenfold specific shift in fluorescence upon binding to this cell line
(Vaughan et al, 1996), as did all of the affinity-matured clones
(Figure 2A). The extent of fluorescent staining seen was less than
that routinely observed with CEA-specific bivalent mAbs (data
not shown), but in all cases the cell population stained specifically
with scFv was homogeneous.
In these experiments, we used the immortalized Chang human
liver cell line as a negative control for CEA expression. We
observed that CEA6 consistently showed crossreactivity to a
subpopulation of Chang cells, as did HBB 11 and TO6D12 to a
lesser extent, while the remainder of the affinity matured clones
showed no crossreactivity (Figure 2B). However, the crossreactive
component in CEA6 was not observed on immunocytochemical
staining of sections of normal human liver (data not shown).
CEA-reactivity of 1251-labelled scFv
The estimated efficiency of the lodoGen method for '251-labelling of
scFv ranged from 10-40% and yielded products with specific activi-
ties in the range 0.5-2 pCi jg-'. This assumed that<95% of["i51]scFv
bound to pre-blocked Sephadex G25 following separation oflabelled
scFv from free iodine in the iodination reaction. This assumption is
supported by the fact that 93-97% ofincorporated counts in the first
column-eluted radioactive peak was TCA precipitable (and remained
T06D12
T06D11
FL1
HBB11
CEA6
T06D12 HBB11
T06D11 CEA6
FL1
Figure 2 1 x 103 flow fluorocytometric events are plotted against number of (A) HeLa CEA transfectants and (B) Chang human liver cells, as stained
specifically by 50 pg ml-' monomeric scFv of Hb-1 (negative control); T06D4; T06D12; HBB11; T06D10; T06D11 and CEA6
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Figure 3 Mean %ID g-1 of tissue at (A) 3 h and (B) 24 h post i.v. administration of [1251]CEA6 (filled bars), ['251]TO6D11 (open bars), [1251]MFE23 (open square
bars) and [1251]FITC-E2 (diagonal stripe bars) to MF1 nulnu mice bearing subcutaneous LS1 74T human colon tumour xenografts. [1251]MFE23 biodistribution at
3 h has been examined previously and was omitted from this experiment. Mean values are derived from n = 4 mice and vertical bars indicate standard deviation
(s.d.) from the mean
so for at least 7 days post iodination), and that 62-92% of the counts
retained CEA specificity when bound to CEA-Sepharose. The
percentage binding ofindividual 1211-labelled scFv to CEA-Sepharose
was as follows: ['25I]CEA6 (70-90%), [1r2I]T06D4 (62-84%),
[125I]TO6Dl2 (83%), ['251IT06D10 (84%), ['15I]HBBll (83%) and
['15I]TO6D 11(71-85%). This compared favourably with 80% of the
counts associated with the murine ['251]MFE23, while <10% of the
negative control, ['251]FITC-E2, showed binding to the CEA column.
Biodistribution in mice bearing LS174T xenografts
An initial study compared the biodistribution of the parental clone
['251]CEA6 with that of ['251]TO6DI1, which had exhibited a
13-fold improvement in K, and sevenfold improvement in Koffrela-
tive to CEA6 (Osbourn et al, 1996). ['951]MFE23 and ['251]FITC-E2
were included as positive and negative controls respectively;
MFE23 biodistribution was only measured at the 24 h timepoint to
minimize the number ofmice required for the experiment.
All CEA-specific scFv exhibited tumour-specific localization at
both 3 h and 24 h post injection (p.i.; Figure 3A and B). The
percentage of injected dose (%ID) associated with tumour at 24 h
was in the range typically seen with scFv (Huston et al, 1993):
[I251]CEA6 generated the highest %ID g-I in tumour (1.6%) with
0.8% and 0.4% for [1251]MFE23 and ['251]TO6D1 I respectively
(Figure 3B). Kidney uptake of all scFv was elevated with respect to
blood at both time points, suggesting renal elimination. After
24 h, the tumour-blood (T:B) ratios were comparable for ["251]CEA6
(22: 1) and ['251]MFE23 (15:1; data not shown), while ['251]TO6D 11
exhibited the lowest tumour-blood ratio (6:1). However, at 48 h p.i.,
the amount of [125I]TO6DI1 associated with tumour had been main-
tained (T:B 6.6:1) whereas [I251]CEA6 had fallen from 22:1 at 24 h
to 3:1 at 48 h (Figure 4). These results strongly suggest that the
prolonged binding of TO6D to tumour relative to CEA6 is, at
least in part, a consequence of its improved K011.
A second study compared the biodistribution of [1251]CEA6 with
[215I]TO6DI0, ['125I]T06D4, ['1'I]TO6D12 and ['251]HBBI1, to
determine whether the tumour targeting of each clone correlated
with its off-rate. Because of the large number of scFv samples,
MFE23, TO6D11 and FITC-E2 were omitted from this particular
study. All clones localized to tumour at 24 h p.i., achieving T:B
ratios > 4 (Figure 5B); the kidney was the route ofexcretion for all
25
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Figure 4 Mean T:B ratio at 3 h, 24 h and 48 h post i.v. administration of
['251]CEA6 (filled bars) and [l251]TO6D11 (open bars) to LS174T xenografted
mice
clones as expected. Tumour-blood (T/B) ratio provided a basis for
ranking the scFv tested in this series: CEA6 (11:1) = T06D12 >
HBB I 1 (6: 1) > T06D10 (4:1) = T06D4. However, when assessed
on the basis of mean %ID g-' in tumour at the same time point
(Figure SA), the opposite ranking was obtained: T06D4 (2%) >
T06D10 (1.3%) = HBBI1 (1.2%) > T06D12 (0.6%) = CEA6
(0.6%). For each scFv, kidney-blood ratio was found to be
inversely proportional to %ID localized in tumour, suggesting that
the extent of scFv retention in the kidney was an additional factor
influencing tumour targeting efficiency.
A third study compared the biodistribution of [251I]CEA6,
['251]TO6D12 and ['251]TO6D4. The three candidates were selected
for re-examination based on the following observations: (1) in
previous experiments in which CEA6 and MFE23 had been
compared, CEA6 had generated comparable, if not superior, T/B
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ratios in mice, of particular significance as MFE23 has been
shown to have clinical utility; (2) in a single study (the second
described above), T06D12 had exhibited similar properties to
CEA6 and (3) in the same experiment, TO6D4 had generated the
highest %ID g-' in tumour (Figure 5A). For the purpose of this
study, a greater range of time points (3 h, 6 h, 18 h and 24 h) was
examined. The data are summarized in Table 2.
['251]CEA6 achieved T/B ratios of 14:1 at 18 h which had
persisted at 24 h (0.5%ID g-' tumour), data consistent with the
previous two studies. The biodistribution data generated for
['21]TO6D4 also appeared to support the findings of the previous
study, with a higher %ID in tumour (1.5%) at 24 h p.i. and lower
T/B ratio (4.5: 1). Again, the lower kidney:blood ratio for
['251]TO6D4 at 24 h suggested a difference from ['25I]CEA6 in
extent ofkidney retention. Tumour uptake of['251]T06D12 (0.4%)
was similar to that obtained with ['251]CEA6 (Table 2) but, in this
study, the T/B ratio appeared to be lower than that measured
previously (6.6:1 as compared with 11:1).
DISCUSSION
We have previously described the isolation by phage display of a
CEA specific scFv, CEA6, from a large unimmunized human library
(Vaughan et al, 1996). The dissociation constant ofCEA6 for CEA is
in the nanomolar range (7.7 x 10-9 M), which is typical of antibodies
isolated from very large repertoires (Perelson and Oster, 1979;
Griffiths et al, 1994; Vaughan et al, 1996). Our early work showed
that the antibody binds CEA-expressing cells by flow cytometry and
immunocytochemistry, and localizes to CEA-expressing human
tumour xenografts in nude mice. Because CEA6 had fulfilled the
specificity requirements as apotential human tumourtargeting agent,
it was subjected to affinity maturation using a combination of low
redundancy mutagenesis in CDR3 ofheavy and light chains and light
chain shuffling (Osbourn et al, 1996). Selection for clones with
longer off-rates (KO,,) than CEA6 was achieved by solution selection
in the presence of excess free antigen (Hawkins et al, 1992).
Our previous work reported the antigenic specificity and binding
kinetics of the CEA6-derived mutants (Osboum et al, 1996). Our
longer term objective was to determine whether the off-rate compo-
nent of affinity would influence the amount of antibody associated
with tumour at different times after intravenous administration. We
carried out the in vivo experiments with CEA6 and all five mutant
scFv (HBB11, TO6D10, T06D4, TO6D12 and TO6D11), spanning
a range ofKo09 values from 6.2 x 10-3 s- to 9.0 x 104s-'.To eliminate
the role of avidity effects in the biodistribution profiles, purified
monomeric fractions of scFv were used for the experiments, because
we and others have observed a tendency of scFv to form dimers
(Griffiths et al, 1992).
One of the advantages ofusing 1211 as the labelling radioisotope is
that the lodoGen method allows more than one atom of iodine to be
introduced per scFv, thereby increasing the sensitivity of detection.
Labelling of scFv with Technetium-99m at single specific sites
remote from the binding domains has been successful for imaging
applications (Liberatore et al, 1995; Verhaar et al, 1996) but is less
sensitive than iodine. However, onedisadvantage ofiodination is that
it modifies tyrosine residues including those in the antigen binding
site. CEA6 and the mutants derived from it have at least 14 tyrosine
residues available for attachment of iodine, some of which are in
complementarity-determining regions, yet in the affinity chromatog-
raphy experiments described here, none of the clones showed
reduced CEA binding specificity following radioiodination. This was
subsequently confirmed in their tumour localization profiles.
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Figure 5 (A) Mean %ID g-' of tissue 24 h post i.v. administration of
["25I]CEA6 (filled bars), ["251]TO6D10 (diagonal stripe bars), [1251]TO6D4 (open
bars), [1251]T06D12 (horizontal stripe bars) and ["251]HBB11 (vertical stripe
bars) to LS174T xenografted mice. Mean values are derived from n = 4 mice
and vertical bars indicate standard deviation (s.d.) from the mean. (B) Mean
tissue:blood ratio 24 h post i.v. administration of [1251]CEA6, [1251T06D10,
1'251]TO6D4, ['251]TO6D12 and ['251]HBB11 to LS174T xenografted mice
Rapid fractional clearance of murine scFv from the blood after
intravenous administration has often been reported to be the deter-
mining factor in the concentration of scFv taken up into tumour
(Colcher et al, 1990; Milenic et al, 1991; Savage et al, 1993). For all
1'21-labelled scFv examined in this study, clearance ofthe bulk ofthe
injected dose was primarily via the kidney at early time points. There
was no significant uptake of radioactivity into any of the normal
tissues at the time points tested, although the degree ofkidney reten-
tion over time varied from clone to clone. The lower tumour-kidney
ratio at 24 h, measured for scFv T06D4, suggested a rate of clear-
ance more typical of Fab' or F(ab')2 fragments (Colcher et al, 1990;
Rowlinson-Busza et al, 1996). However, whole-body clearance rates
determined for T06D4 in parallel with T06D12 and CEA6 subse-
quently showed indistinguishable t,,, measurements of approxi-
mately 2 h (data not shown).
All scFv were preferentially localized in tumour 6 h after injec-
tion, and by 24 h the amount of the injected dose retained at the
tumour site varied from one scFv to another. The scFv with the
lowestKM,T06D 1 did not show the highest T/B ratio at 24 h, and it
was in fact CEA6 which gave the most consistentperformance in the
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Table 2 Comparison of biodistribution of CEA6, T06D12 and T06D4 scFv
3h 6h 18h 24h
CEA 6
Blood 4.20 + 1.37 [1.0] 2.23 + 0.43 [1.0] 0.09 + 0.01 [1.0] 0.05 + 0.02 [1.0]
Liver 1.74 ± 0.50 [0.4] 2.62 + 2.70 [1.4] 0.08 + 0.02 [0.9] 0.06 + 0.01 [1.3]
Kidney 9.99+ 3.30 [2.4] 2.20± 0.31 [1.0] 0.26+ 0.14 [2.6] 0.14 ± 0.02 [3.5]
Lung 3.00 + 0.91 [0.7] 1.66 + 0.38 [0.7] 0.08 + 0.02 [0.9] 0.06 ± 0.01 [1.5]
Spleen 1.86 ± 0.52 [0.5] 1.06 + 0.17 [0.5] 0.10± 0.05 [1.1] 0.07+ 0.01 [1.7]
Colon 2.06 + 0.73 [0.5] 1.06 ± 0.25 [0.5] 0.07 + 0.02 [0.8] 0.06 ± 0.02 [1.3]
Muscle 1.26+ 0.57 [0.3] 0.53 ± 0.10 [0.2] 0.05 ± 0.02 [0.5] 0.03+ 0.01 [0.8]
Femur 1.87 ± 0.65 [0.4] 0.97 + 0.22 [0.4] 0.07 + 0.02 [0.8] 0.06 ± 0.01 [1.4]
Tumour 5.78 + 1.14 [1.4] 2.95+ 0.91 [1.4] 1.36 ± 0.76 [14.0] 0.46+ 0.02 [14.6]
T06D12
Blood 3.54+ 1.01 [1.0] 2.65 ± 0.62 [1.0] 0.07 +0.03 [1.0] 0.05+ 0.02 [1.0]
Liver 1.58 ± 0.49 [0.4] 1.19 + 0.34 [0.5] 0.08 ± 0.02 [1.1] 0.05+ 0.01 [1.1]
Kidney 4.65+ 1.32 [1.3] 2.41 + 0.40 [0.9] 0.20 ± 0.05 [2.9] 0.14+ 0.03 [2.7]
Lung 2.39 ± 0.61 [0.7] 1.84 ± 0.42 [0.7] 0.09 ± 0.03 [1.2] 0.06 + 0.01 [1.2]
Spleen 1.57+0.38 [0.5] 1.19+0.29 [0.5] 0.07+0.02 [1.1] 0.07±0.03 [1.6]
Colon 1.58 + 0.45 [0.5] 2.40 ± 1.07 [0.9] 0.06 + 0.02 [0.9] 0.04 + 0.01 [0.9]
Muscle 0.99 + 0.32 [0.3] 0.70 + 0.12 [0.3] 0.05+ 0.02 [0.7] 0.04+ 0.01 [0.8]
Femur 1.61 +0.34 [0.5] 1.13±0.19 [0.4] 0.07+0.02 [1.1] 0.07+0.01 [1.5]
Tumour 4.17+ 1.34 [1.2] 3.24+ 0.71 [1.2] 0.40 + 0.12 [5.9] 0.35+ 0.15 [6.6]
T06D4
Blood 6.84+ 1.10 [1.0] 3.17 ± 1.07 [1.0] 0.37± 0.02 [1.0] 0.35± 0.06 [1.0]
Liver 2.95+0.53 [0.4] 1.41 + 0.31 [0.5] 0.19 +0.01 [0.5] 0.20+0.03 [0.6]
Kidney 7.96 + 1.41 [1.2] 2.95 ± 1.00 [0.9] 0.53 + 0.04 [1.5] 0.46 + 0.02 [1.4]
Lung 4.11 +0.67 [0.6] 1.88±0.65 [0.6] 0.25+0.05 [0.7] 0.23+0.05 [0.7]
Spleen 2.48+ 0.40 [0.4] 1.30 ± 0.41 [0.4] 0.16+ 0.01 [0.4] 0.17+ 0.03 [0.5]
Colon 2.08 ± 0.28 [0.3] 1.04 + 0.42 [0.3] 0.08 + 0.01 [0.2] 0.09 + 0.03 [0.3]
Muscle 1.04 + 0.22 [0.2] 0.59 ± 0.36 [0.2] 0.05 0.004 [0.2] 0.04+0.003 [0.1]
Femur 1.71 +0.34 [0.3] 0.76 ± 0.30 [0.2] 0.10+0.01 [0.3] 0.08 0.02 [0.2]
Tumour 8.32 ± 1.40 [1.2] 4.54 ± 1.43 [1.5] 2.69 + 1.39 [7.4] 1.53+0.22 [4.5]
Mean %ID/g of tissue at specified time points after i.v. administration of [251]CEA6, [251]TO6D12 and [251]TO6D4 scFv to LS174T tumour
xenograft-bearing mice. Mean values are derived from n=4 mice + standard deviation (s.d.) from mean. Mean tissue-blood ratios are
given in square parentheses and are determined from the mean %ID/g of the tissues divided by the %ID/g in blood.
three experiments, with T/B ratios as high as 22:1 at 24h. It is
possible that subtle differences in biodistribution do indeed exist
between individual antibodies in the panel, and even that the differ-
ence correlates with off-rate, as T06D11 showed improved tumour
retention at 48 h relative to CEA6; however, one could argue that the
improved T/B ratio for T06D11 at later timepoints could be due to
reduced kidney retention. Furthermore, it was not possible in these
experiments to demonstrate agradientofprolonged tumourresidence
time corresponding directly to the respective off-rate of the scFv. Of
additional relevance to this is the effect oftumourantigen concentra-
tion on the degree of antibody localization: in the LS174T tumour
xenograft model, the abundant expression of CEA may exceed the
concentration at which increasing the affinity could have a measur-
able effect. This would not be expected in colorectal tumours in man,
which show large individual variations in CEA concentration.
Because the differences in off-rate between the clones are all
within an order ofmagnitude and are measured against abackground
ofrapid pharmacokinetic clearance, it may not be possible to estab-
lish a tumour targeting ranking for clones in scFv format.
Reformatting the scFv as higher molecular weight proteins, or using
chemical modification to increase their residence time in vivo, could
be ways of analysing the influence of off-rate more closely. The
majority of studies in the literature correlating affinity with tumour
uptake have been carried out with intact monoclonal antibodies, or
fragments derived by proteolytic digestion that have a longer serum
half-life than scFv. In a study of the uptake of rodent mAbs into
CEA-expressing tumours inhumans, Sharkey et al (1993) concluded
that ahigh-affinity mAb would achieve improved tumouruptake and
longer residence time at the tumour. However, they also conceded
that the bulk of an injected high affinity antibody would be absorbed
by CEA shed in the serum and by cells at the tumour periphery,
whereas a lower affinity mAb would have the chance to penetrate to
CEA positive cells deeper in the tumour and thereby result in a better
therapeutic agent.
As well as the different patterns of in vivo behaviour ofthe panel
ofscFv, flow cytometry has revealed differences in extent ofbinding
to a human liver cell line: CEA6, HBB 11 and, to a very small extent,
T06D 12 were partially cross-reactive with Chang cells, while the
remaining affinity-matured clones were not. Although structurally
related markers of the CEA superfamily are known to be expressed
on liver (Hinoda et al, 1988), the binding of CEA6, HBB11 and
T06D 12 cannot be explained as cross-reactivity to such molecules,
as normal human liver stained negative by immunocytochemistry for
all ofthe scFv in the study. It is notpossible toexplain the cross-reac-
tive component in these antibodies on the basis of sequence, as there
is no light chain sequence consensus between CEA6, HBB11 and
T06DI2 that distinguishes them from the other clones (Osbourn et
al, 1996). Likewise, the extent oflivercell binding does not appear to
increase with increasing affinity for CEA. However, because we had
not observed increased liver retention of ['251]CEA6, ['251]HBB11 or
['25I]TO6D12 in mice, the results suggest that the element of cross-
reactivity is only relevant to a subcomponent of Chang human liver
cells, through the binding ofan unknown cell-surface antigen.
It has recently been shown that a radiolabelled scFv specific for
human CEA is a potent tumourimaging agent, achieving exceptional
T/B ratios in patients (Begent et al, 1996). The scFv in question,
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MFE23, was isolated from aphage display library constructed from a
CEA-immunized mouse and has an affinity for CEA of 2.5 x 10-9 M
(Chester et al, 1994). Our work demonstrates that CEA6 compares
very favourably with MFE23 in a mouse tumour xenograft model
and has an affinity for CEA in the same range. However, one clear
distinction between the two antibodies is that while MFE23 was
derived from antigenic selection in a mouse, CEA6 has been selected
directly from a non-immunized human library and functions in
tumour targeting without additional affinity maturation. This study
has shown that CEA6 has all ofthe essential properties for reformat-
ting as a higher molecular weight molecule to prolong its in vivo
half-life and thereby improve its performance as a fully human thera-
peutic agent. These studies are currently in progress.
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